HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Experience with intravaginal misoprostol in the management of intra-uterine fetal death.

Abstract
This collaborative study between the departments of Obstetrics and Gynaecology of the University College Hospital, Ibadan and Federal Medical Centre, Abeokuta assessed the value of intravaginal misoprostol in the management of intra-uterine fetal death. Fifty-six women at gestational ages between 17 weeks and term admitted for intra-uterine death with no contraindications to misoprostol received 400mcg of misoprostol administered intravaginally 12-hourly, until the establishment of effective uterine contractions. The mean gestational age was 27.9 weeks+/-7.1(SD) and the mean Bishop score was 2.7+/-2.4(SD). The mean duration of onset of contractions was 5.0 hours+/-8.4 (SD); the mean induction-delivery interval was 17.5 hours+/-6.3(SD). Ninety three percent of the women had expelled within 48 hours. Successful induction was achieved in all women. Prophylactic vacuum aspiration was performed (lower gestation only) in 19.6% of cases. Fever, nausea and vomiting were the commonest side effects (7.1%). Neither gestational age nor the cervical score significantly affected the insertion-contraction or induction-delivery intervals. Intra-vaginal Misoprostol at the dosage administered is safe, effective and reduces staff workload.
AuthorsA O Fawole, A O Adekunle, O S Sotiloye, A O Arowojolu, E O Otolorin
JournalAfrican journal of medicine and medical sciences (Afr J Med Med Sci) Vol. 33 Issue 2 Pg. 105-8 (Jun 2004) ISSN: 0309-3913 [Print] Nigeria
PMID15565925 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)
Chemical References
  • Abortifacient Agents, Nonsteroidal
  • Misoprostol
Topics
  • Abortifacient Agents, Nonsteroidal (therapeutic use)
  • Administration, Intravaginal
  • Adult
  • Drug Administration Schedule
  • Female
  • Fetal Death
  • Gestational Age
  • Humans
  • Labor, Induced (methods)
  • Misoprostol (therapeutic use)
  • Pregnancy
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: